CRON Stock Rises 17% in Three Months: Time to Buy the Dip or Cash Out?
Cronos Group stock climbs 17% in three months on strong revenue growth and margin gains, but rising competition and regulatory risks raise questions about its upside.
CRON - Cronos Group Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$3.15
DETAILS
HIGH:
$4.50
LOW:
$2.30
MEDIAN:
$2.90
CONSENSUS:
$3.15
DOWNSIDE:
1.87%
Stock News
Cronos Group Inc. to Hold 2026 Third Quarter Earnings Conference Call on November 5, 2026
TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 third quarter earnings conference call on Thursday, November 5, 2026, at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks.
Financial Survey: Eton Pharmaceuticals (NASDAQ:ETON) vs. Cronos Group (NASDAQ:CRON)
Cronos Group (NASDAQ: CRON - Get Free Report) and Eton Pharmaceuticals (NASDAQ: ETON - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends. Earnings and Valuation This table compares Cronos
Cronos Group Inc. $CRON Shares Newly Acquired by Bank of America Corp DE
Bank of America Corp DE bought a new position in Cronos Group Inc. (NASDAQ: CRON) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 157,631 shares of the company's stock, valued at approximately $438,000. Other institutional investors and hedge funds have also made changes
Cronos Group Inc. (CRON:CA) Analyst/Investor Day Transcript
Cronos Group Inc. (CRON:CA) Analyst/Investor Day Transcript
Cronos Group Investor Day Highlights Cannabis Growth, Cash Flow and Global Ambitions
Cronos Group NASDAQ: CRON used its first Investor Day to outline its cultivation, genetics, brand and financial strategy, emphasizing its purpose-built greenhouse partnership with Mucci Farms, continued international expansion and a focus on cash flow generation.
Cronos Hosts 2026 Investor Day
TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is hosting its first Investor Day today, September 24, 2026, at its Cronos Growing Company Inc. Kingsville location.
Head to Head Contrast: Lyra Therapeutics (OTCMKTS:LYRA) versus Cronos Group (NASDAQ:CRON)
Cronos Group (NASDAQ: CRON - Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends. Profitability This table compares Cronos Group and
Cronos: Invest In Cannabis With 50% Net Cash And GAAP Profitability
Cronos Group Inc. is upgraded to a Buy, driven by a best-in-class balance sheet and improved profitability. CRON boasts $827 million in cash, no debt, and strong international expansion, with adjusted gross margins reaching 46%. Profitability is supported by disciplined cost management and positive GAAP operating profit, distinguishing CRON from Canadian peers.
Cronos to Host 2026 Investor Day at its Cronos GrowCo Facility in Kingsville, Ontario
Registration is now open for Cronos' first Investor Day, which will be hosted by the Cronos Leadership Team, on September 24, 2026 Registration is now open for Cronos' first Investor Day, which will be hosted by the Cronos Leadership Team, on September 24, 2026
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Here is how Cronos Group (CRON) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Cronos' brand Spinach® Expands its Best-Selling Lineups of Edibles and Vapes
TORONTO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is expanding its lineup of edible multipacks with the SOURZ by Spinach® Blue Raspberry Lemonade Fully Blasted multipack, featuring its first live resin gummy. This month the brand will also launch new flavors in its best-selling lineup of vape cartridges, Strawberry Banana and Sweet Citrus Punch.
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock
Cronos Group (CRON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Marijuana reform is emerging as a midterm elections issue on both sides of the aisle
With November's pivotal midterm elections fast approaching, cannabis reform is emerging as an issue. Two states, Massachusetts and Idaho, will vote on ballot initiatives regarding legalization, and in several others, including Kansas and Iowa, gubernatorial candidates are debating cannabis matters.
Cronos Group: This Cannabis Name Isn't Reliant On U.S. Legalization Efforts
Cronos delivered a Q2 2026 earnings report that met bullish investor expectations. Strong quarterly performance reinforces the investment thesis for CRON's growth trajectory. Management execution and financial results support a positive outlook for CRON.
Cronos: Strong Quarter, And The Outlook For The Future Is Positive Thanks To M&A
Cronos Group Inc. is rapidly expanding internationally, leveraging European legalization momentum and the CanAdelaar acquisition to become a major European cannabis player. Q2 results showed 58% YoY revenue growth to $53M, with margins benefiting from favorable sales mix and stable operating expenses. CRON maintains a robust balance sheet with nearly $800M in cash and short-term investments versus $56M in current liabilities, supporting buybacks and future M&A.
Cronos Group Inc. (CRON:CA) Q2 2026 Earnings Call Transcript
Cronos Group Inc. (CRON:CA) Q2 2026 Earnings Call Transcript
Cronos Group Q2 Earnings Call Highlights
Cronos Group NASDAQ: CRON reported record second-quarter net revenue, gross profit and adjusted EBITDA for 2026, supported by growth in Israel, Canada and other international markets, including Germany.
Cronos Group (CRON) Surpasses Q2 Earnings and Revenue Estimates
Cronos Group (CRON) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.1 per share a year ago.
Price Targets
Cronos Group (CRON) PT Raised to $2.30 at Bernstein
$2.30
(was $2.70)
Nadine Sarwat
·
Bernstein
Cronos Group (CRON) PT Lowered to $2.30 at BofA Securities
$2.30
(was $2.32)
Lisa Lewandowski
·
Bank of America Securities
Barclays Maintains Equal-Weight on Cronos Group, Lowers Price Target to $3.5
$3.50
(was $2.93)
Barclays
Cronos Group upgraded to Hold from Sell at Canaccord
$4.50
(was $3.18)
Matt Bottomley
·
Canaccord Genuity